Autopsy report · NCT04711161

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

“Business/Commercial Reasons”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 73 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

Green3Bio, Inc.

Sponsor type

Industry

Conditions

Ovarian Tumors

Interventions

GRN-300; Paclitaxel

Participants

73 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet
  “Commercial reasons” (94% match in meaning)
• A Clinical Study of V540A in Healthy Female Participants (V540A-005)
  “Business Reasons” (87% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (82% match in meaning)
• StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
  “Business Reason” (80% match in meaning)
• Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
  “For business reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.